## Weihong Ding

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9765598/publications.pdf Version: 2024-02-01



WEIHONG DING

#	Article	IF	CITATIONS
1	Mechanisms of enzalutamide resistance in castrationâ€resistant prostate cancer and therapeutic strategies to overcome it. British Journal of Pharmacology, 2021, 178, 239-261.	5.4	53
2	Chronic Psychological Stress Attenuates the Efficacy of anti-PD-L1 Immunotherapy for Bladder Cancer in Immunocompetent Mice. Cancer Investigation, 2021, 39, 571-581.	1.3	7
3	Depression Induced by CUMS Leads to Bladder Cancer Development and Local Tumor Immunosuppression in Mice. Journal of Oncology, 2021, 2021, 1-10.	1.3	6
4	Increased Risk of Recurrence of Non-Muscle Invasive Bladder Cancer Associated With Psychological Distress: A Prospective Cohort Study. Psychiatry Investigation, 2021, 18, 718-727.	1.6	0
5	Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer. Molecular Pharmaceutics, 2021, 18, 4015-4028.	4.6	24
6	The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer. Frontiers in Oncology, 2021, 11, 752860.	2.8	6
7	SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer. Theranostics, 2020, 10, 1619-1632.	10.0	43
8	Chronic Unpredictable Mild Stress Accelerates the Growth of Bladder Cancer in a Xenograft Mouse Model. Psychology Research and Behavior Management, 2020, Volume 13, 1289-1297.	2.8	9
9	Coatomer subunit beta 2 (COPB2), identified by label-free quantitative proteomics, regulates cell proliferation and apoptosis in human prostate carcinoma cells. Biochemical and Biophysical Research Communications, 2018, 495, 473-480.	2.1	15
10	NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP. Chemotherapy, 2018, 63, 191-197.	1.6	3
11	A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy. Annals of Clinical and Laboratory Science, 2018, 48, 18-28.	0.2	1
12	COPB2 Is Upregulated in Prostate Cancer and Regulates PC-3 Cell Proliferation, Cell Cycle, and Apoptosis. Archives of Medical Research, 2016, 47, 411-418.	3.3	30
13	Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World Journal of Urology, 2015, 33, 1951-1957.	2.2	20
14	Retroperitoneal Laparoscopic Ureterolithotomy for Proximal Ureteral Calculi in Selected Patients. Scientific World Journal, The, 2014, 2014, 1-5.	2.1	4
15	Are EORTC risk tables suitable for Chinese patients with non-muscle-invasive bladder cancer?. Cancer Epidemiology, 2014, 38, 157-161.	1.9	13
16	The prognostic value of C-reactive protein in renal cell carcinoma: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 50.e1-50.e8.	1.6	58
17	Ki-67 is an independent indicator in non–muscle invasive bladder cancer (NMIBC); Combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 42.e13-42.e19.	1.6	46
18	Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy. Proteome Science, 2011, 9, 22.	1.7	37